121 related articles for article (PubMed ID: 36599228)
21. Isoquercitrin suppresses colon cancer cell growth in vitro by targeting the Wnt/β-catenin signaling pathway.
Amado NG; Predes D; Fonseca BF; Cerqueira DM; Reis AH; Dudenhoeffer AC; Borges HL; Mendes FA; Abreu JG
J Biol Chem; 2014 Dec; 289(51):35456-67. PubMed ID: 25359775
[TBL] [Abstract][Full Text] [Related]
22. AlphaScreen selectivity assay for β-catenin/B-cell lymphoma 9 inhibitors.
Zhang M; Wisniewski JA; Ji H
Anal Biochem; 2015 Jan; 469():43-53. PubMed ID: 25312469
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of β-catenin/B cell lymphoma 9 protein-protein interaction using α-helix-mimicking sulfono-γ-AApeptide inhibitors.
Sang P; Zhang M; Shi Y; Li C; Abdulkadir S; Li Q; Ji H; Cai J
Proc Natl Acad Sci U S A; 2019 May; 116(22):10757-10762. PubMed ID: 31088961
[TBL] [Abstract][Full Text] [Related]
24. Discovery of 2-(isoxazol-5-yl)phenyl 3,4-dihydroxybenzoate as a potential inhibitor for the Wnt/β-catenin pathway.
Dong Y; Liu M; Mao Y; Wu S; Wen J; Lu J; Yang Y; Ruan S; Li L; Liu X; Zhang J; Liao S; Dong L
Bioorg Chem; 2022 Nov; 128():106116. PubMed ID: 36063753
[TBL] [Abstract][Full Text] [Related]
25. BCL9-2 binds Arm/beta-catenin in a Tyr142-independent manner and requires Pygopus for its function in Wg/Wnt signaling.
Hoffmans R; Basler K
Mech Dev; 2007 Jan; 124(1):59-67. PubMed ID: 17113272
[TBL] [Abstract][Full Text] [Related]
26. Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction.
Kawamoto SA; Coleska A; Ran X; Yi H; Yang CY; Wang S
J Med Chem; 2012 Feb; 55(3):1137-46. PubMed ID: 22196480
[TBL] [Abstract][Full Text] [Related]
27. Quercetin inhibit human SW480 colon cancer growth in association with inhibition of cyclin D1 and survivin expression through Wnt/beta-catenin signaling pathway.
Shan BE; Wang MX; Li RQ
Cancer Invest; 2009 Jul; 27(6):604-12. PubMed ID: 19440933
[TBL] [Abstract][Full Text] [Related]
28. Discovery of an Orally Bioavailable Small-Molecule Inhibitor for the β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction.
Wang Z; Zhang M; Quereda V; Frydman SM; Ming Q; Luca VC; Duckett DR; Ji H
J Med Chem; 2021 Aug; 64(16):12109-12131. PubMed ID: 34382808
[TBL] [Abstract][Full Text] [Related]
29. The Tumor-Suppressor WWOX and HDAC3 Inhibit the Transcriptional Activity of the β-Catenin Coactivator BCL9-2 in Breast Cancer Cells.
El-Hage P; Petitalot A; Monsoro-Burq AH; Maczkowiak F; Driouch K; Formstecher E; Camonis J; Sabbah M; Bièche I; Lidereau R; Lallemand F
Mol Cancer Res; 2015 May; 13(5):902-12. PubMed ID: 25678599
[TBL] [Abstract][Full Text] [Related]
30. Modulating β-catenin/BCL9 interaction with cell-membrane-camouflaged carnosic acid to inhibit Wnt pathway and enhance tumor immune response.
Gao R; Zheng X; Jiang A; He W; Liu T
Front Immunol; 2023; 14():1274223. PubMed ID: 37881428
[TBL] [Abstract][Full Text] [Related]
31. Crystal structure of a beta-catenin/BCL9/Tcf4 complex.
Sampietro J; Dahlberg CL; Cho US; Hinds TR; Kimelman D; Xu W
Mol Cell; 2006 Oct; 24(2):293-300. PubMed ID: 17052462
[TBL] [Abstract][Full Text] [Related]
32. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/β-catenin pathway.
Li B; Cai S; Zhao Y; He Q; Yu X; Cheng L; Zhang Y; Hu X; Ke M; Chen S; Zou M
Oncotarget; 2016 Dec; 7(49):81026-81048. PubMed ID: 27835587
[TBL] [Abstract][Full Text] [Related]
33. Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.
Hoggard LR; Zhang Y; Zhang M; Panic V; Wisniewski JA; Ji H
J Am Chem Soc; 2015 Sep; 137(38):12249-60. PubMed ID: 26352795
[TBL] [Abstract][Full Text] [Related]
34. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
[TBL] [Abstract][Full Text] [Related]
35. Direct targeting of β-catenin in the Wnt signaling pathway: Current progress and perspectives.
Wang Z; Li Z; Ji H
Med Res Rev; 2021 Jul; 41(4):2109-2129. PubMed ID: 33475177
[TBL] [Abstract][Full Text] [Related]
36. Cell-type-specific function of BCL9 involves a transcriptional activation domain that synergizes with beta-catenin.
Sustmann C; Flach H; Ebert H; Eastman Q; Grosschedl R
Mol Cell Biol; 2008 May; 28(10):3526-37. PubMed ID: 18347063
[TBL] [Abstract][Full Text] [Related]
37. Wnt status-dependent oncogenic role of BCL9 and BCL9L in hepatocellular carcinoma.
Huge N; Sandbothe M; Schröder AK; Stalke A; Eilers M; Schäffer V; Schlegelberger B; Illig T; Vajen B; Skawran B
Hepatol Int; 2020 May; 14(3):373-384. PubMed ID: 31440992
[TBL] [Abstract][Full Text] [Related]
38. Quercetin reduces pluripotency, migration and adhesion of human teratocarcinoma cell line NT2/D1 by inhibiting Wnt/β-catenin signaling.
Mojsin M; Vicentic JM; Schwirtlich M; Topalovic V; Stevanovic M
Food Funct; 2014 Oct; 5(10):2564-73. PubMed ID: 25138740
[TBL] [Abstract][Full Text] [Related]
39. An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.
de la Roche M; Rutherford TJ; Gupta D; Veprintsev DB; Saxty B; Freund SM; Bienz M
Nat Commun; 2012 Feb; 3():680. PubMed ID: 22353711
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia-inducible factor 1α induces osteo/odontoblast differentiation of human dental pulp stem cells via Wnt/β-catenin transcriptional cofactor BCL9.
Orikasa S; Kawashima N; Tazawa K; Hashimoto K; Sunada-Nara K; Noda S; Fujii M; Akiyama T; Okiji T
Sci Rep; 2022 Jan; 12(1):682. PubMed ID: 35027586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
